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Abstract
Ribonucleoside analogues have potential utility as anti-viral, -parasitic, -bacterial and -cancer agents. However, their clinical
applications have been limited by off target effects. Development of antiviral ribonucleosides for treatment of hepatitis C
virus (HCV) infection has been hampered by appearance of toxicity during clinical trials that evaded detection during
preclinical studies. It is well established that the human mitochondrial DNA polymerase is an off target for
deoxyribonucleoside reverse transcriptase inhibitors. Here we test the hypothesis that triphosphorylated metabolites of
therapeutic ribonucleoside analogues are substrates for cellular RNA polymerases. We have used ribonucleoside analogues
with activity against HCV as model compounds for therapeutic ribonucleosides. We have included ribonucleoside analogues
containing 29-C-methyl, 49-methyl and 49-azido substituents that are non-obligate chain terminators of the HCV RNA
polymerase. We show that all of the anti-HCV ribonucleoside analogues are substrates for human mitochondrial RNA
polymerase (POLRMT) and eukaryotic core RNA polymerase II (Pol II) in vitro. Unexpectedly, analogues containing 29-C-
methyl, 49-methyl and 49-azido substituents were inhibitors of POLRMT and Pol II. Importantly, the proofreading activity of
TFIIS was capable of excising these analogues from Pol II transcripts. Evaluation of transcription in cells confirmed sensitivity
of POLRMT to antiviral ribonucleosides, while Pol II remained predominantly refractory. We introduce a parameter termed
the mitovir (mitochondrial dysfunction caused by antiviral ribonucleoside) score that can be readily obtained during
preclinical studies that quantifies the mitochondrial toxicity potential of compounds. We suggest the possibility that
patients exhibiting adverse effects during clinical trials may be more susceptible to damage by nucleoside analogs because
of defects in mitochondrial or nuclear transcription. The paradigm reported here should facilitate development of
ribonucleosides with a lower potential for toxicity.
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Introduction
Many prokaryotic and eukaryotic organisms have evolved to
produce ribonucleoside analogues with antibiotic activity [1–3].
Many of these natural products have been shown to have
therapeutic efficacy in the treatment of microbial infections and
cancer [1–3]. These natural therapeutic ribonucleoside analogues
have inspired the design of synthetic analogues for a variety of
clinical indications [1,4–7].
Hepatitis C virus (HCV) infection is the leading cause of end-
stage liver disease and liver cancer in North America and Europe
[8]. Among classes of agents being pursued as next generation
HCV inhibitors, ribonucleoside analogues that inhibit viral RNA
synthesis subsequent to incorporation of their phosphorylated
metabolites into nascent viral RNA by the HCV RNA-dependent
RNA polymerase [RdRp; HCV non-structural protein 5B (NS5B)]
have emerged as perhaps the most promising due to their
pangenotype activity and high barrier to resistance development
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[4,9–11]. After more than a decade, however, not a single anti-
HCV ribonucleoside has made it through phase 3 clinical trials
due mainly to the manifestation of adverse effects during clinical
development.
Promising results for the nucleoside analog MK608 (7-deaza-29-
C-methyladenosine) observed in chimps [12,13] have never been
replicated in the clinic for undisclosed reasons. Particularly
frustrating and expensive has been the failure of candidates late
in phase 2 studies. The first two nucleoside analogs to enter clinical
development, NM283 (prodrug of 29-C-methylcytosine) and
RG1626 (prodrug of 49-azidocytosine), were stopped due to their
respective associations with dose limiting gastrointestinal and
hematologic toxicity [4,10]. PSI-938 (prodrug of 29-deoxy-29-
fluoro-29-C-methylguanosine) was also placed on clinical hold
following the observation of laboratory abnormalities associated
with liver functional tests [14]. Most recently, clinical development
of another promising candidate BMS-986094 (prodrug of 29-C-
methylguanosine) was stopped [15]. Many other nucleoside
analogs have likely failed during preclinical development due to
toxicity.
It has been recognized that many adverse effects associated with
nucleoside reverse transcriptase inhibitors (NRTIs), analogues of
29-deoxynucleosides, used for the treatment of human immuno-
deficiency virus (HIV) and hepatitis B virus (HBV) are likely
precipitated by mitochondrial toxicity [16–18]. The potential for
severe consequences caused by NRTI induced mitochondrial
toxicity was punctuated by the observation of hepatotoxicity
during clinical trials of the anti-HBV drug candidate fialuridine
[19]. After entering the cell NRTIs and their phosphorylated
metabolites partition between the cytoplasm and mitochondria
facilitated by nucleoside and nucleotide transporters [16,20]. In
mitochondria, many triphosphorylated NRTIs serve as substrates
for the mitochondrial DNA polymerase gamma (Pol c) [17,21].
Because mtDNA is present in vast excess of the level that is
required to support mitochondrial function, reduction of mtDNA
copy number will not manifest in preclinical assays traditionally
employed to evaluate compound toxicity [22]. The recognition of
Pol c as an off target of NRTIs therefore required direct
approaches, including development of specific biochemical assays
to assess the potential of preclinical candidates to elicit mitochon-
drial dysfunction [17,21,23].
mtDNA encodes 13 proteins required for production of ATP by
oxidative phosphorylation, as well as all of the rRNAs and tRNAs
required for translation within mitochondria of the corresponding
13 mRNAs. Therefore, reduction of mtDNA gene expression can
lead to mitochondrial dysfunction [24]. Evaluation of antiviral
ribonucleoside toxicity in vitro typically measures the effect of a
compound on the intracellular concentration of ATP [25]. The
ATP level clearly provides an indication of the energy status of the
cell and is thought to be a useful surrogate for mitochondrial
(dys)function. To date, not a single study has evaluated directly the
impact of antiviral ribonucleoside treatment of cells on mitochon-
drial transcription. When assessed, nuclear transcription has often
been ruled out as an off target for antiviral ribonucleotides [26,27].
Here we present biochemical and cellular evidence that antiviral
ribonucleoside triphosphates are substrates for the human
mitochondrial RNA polymerase (POLRMT) as well as the core
polymerase of eukaryotic RNA polymerase II (Pol II). In our
analysis, we included analogues containing substituents present in
several anti-HCV lead compounds that have been termed non-
obligate chain terminators because they contain a 39-OH group
yet prevent elongation of nascent viral RNA. To our surprise, all of
the non-obligate chain terminators inhibited RNA elongation by
POLRMT and Pol II as well. The addition of transcription factor
S-II (TFIIS) to Pol II reactions reduced substantially the level of
analogue incorporated, thus explaining the relatively reduced
effect of the analogues on Pol II-dependent transcription in cells.
The efficiency of incorporation by POLRMT in vitro predicted
outcomes in cells when normalized for intracellular metabolism of
the antiviral ribonucleoside to the triphosphorylated form.
We present evidence that attrition during clinical studies of
ribonucleosides with anti-HCV activity may be a reflection of
inhibited mitochondrial gene expression. The potential for these
effects is likely missed during in vitro studies completed in cell
culture because traditional assays only evaluate ATP output. Early
clinical studies may not detect adverse events because a sufficient
number of patients are not exposed to identify those most sensitive
to mitochondrial toxicity. Mitochondrial toxicity has been
characterized as a threshold effect [22,24] and duration of the
insult and the genetic predisposition of patients may be important
factors in the severity of adverse events observed. We propose that
genetic determinants of sensitivity to therapeutic nucleosides will
not only include pathways required for mitochondrial function but
also pathways that contribute to the fidelity of nuclear transcrip-
tion.
Results
Antiviral ribonucleoside triphosphates are substrates for
POLRMT
Development of antiviral ribonucleosides targeting HCV NS5B
has been thwarted by the tendency for many lead compounds to
elicit adverse effects either in Investigational New Drug (IND)-
enabling animal studies or, worse, in patients in the clinic [4,10]. It
is becoming increasingly clear that late-stage attrition of drug
candidates is often caused by off targets affecting mitochondrial
function [28]. Moreover, it is well documented that the tripho-
sphorylated metabolites of nucleoside reverse transcriptase inhib-
itors (NRTIs) are substrates for Pol c, leading to reduced
mitochondrial DNA copy number and eventually mitochondrial
dysfunction [17,21,23].
We recently developed the biochemical tools to study
substrate utilization by POLRMT in vitro, placing us in a
Author Summary
Ribonucleoside analogues have potential utility as anti-
viral, -parasitic, -bacterial and -cancer agents. However,
their clinical applications have been limited by side effects
of unknown origin. Here we show in biochemical and cell-
based studies that antiviral ribonucleotide analogues are
substrates for human mitochondrial RNA polymerase
(POLRMT) and eukaryotic core RNA polymerase II (Pol II)
in vitro. Analogues that terminate RNA synthesis by viral
RNA polymerases also inhibit these cellular RNA polymer-
ase. Importantly, the TFIIS proofreading activity of Pol II is
capable of excising these analogues from Pol II transcripts.
We introduce a parameter termed the mitovir (mitochon-
drial dysfunction caused by antiviral ribonucleoside) score
that can be readily obtained during preclinical studies that
quantifies the mitochondrial toxicity potential of com-
pounds. We suggest the possibility that patients exhibiting
adverse effects during clinical trials may be more suscep-
tible to damage by nucleoside analogs because of defects
in mitochondrial or nuclear transcription. The paradigm
reported here should facilitate development of ribonucle-
osides with a lower potential for toxicity.
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unique position to determine the extent to which utilization of
antiviral ribonucleoside triphosphates by POLRMT may
contribute to attrition [29,30]. For this study, we selected the
panel of purine and pyrimidine analogues shown in Figure 1A.
This panel contains modifications to the base or ribose found in
past and/or current clinical candidates for treatment of HCV
[4,9–11,31–35]. Ribavirin was included to set the baseline for
‘‘tolerable’’ values of any observed off-target activity. All of
these analogues were converted to the triphosphate in cells;
however, the steady-state levels varied from less than 0.15 mM
to 3.5 mM (Table 1). For 29-C-methyladenosine, we also
determined the concentration of the triphosphate in isolated
mitochondria. This value was 210 mM (Table S1), a value in
the range determined when total cellular pools were evaluated
(Table 1). All of the ribonucleosides except 49-methylcytidine
inhibited replication (Table 1, EC50) of HCV in the human
hepatoma cell line, Huh-7, at a concentration that was, in most
cases, below the value of ribonucleoside required to reduce the
intracellular ATP levels by 50% (CC50) as measured by a
luciferase reporter assay (Table 1).
Figure 1. Antiviral ribonucleoside triphosphates are substrates for POLRMT. (A) Nucleoside analogs used in this study. (B) RNA-primed
DNA templates. The first templating base is underlined. (C) Nucleoside analog incorporation catalyzed by POLRMT. Reaction products from POLRMT-
catalyzed nucleotide incorporation using the indicated nucleoside analog triphosphate and RNA primer/DNA template nucleic acid scaffolds shown
in panel b. Reactions proceeded for 30 s. RNA primer was extended to n+1 in the presence of each nucleoside triphosphate. (D) Percentage of RNA
product relative to correct nucleotide (ATP, CTP, GTP or UTP) is shown. Error bars represent s.e.m. n = 3. Both 29-deoxy-29-fluoro-29-C-methyl-UTP and
ribavirin triphosphate were the least incorporated nucleoside analogs. (E) Inhibition of mitochondrial transcription by ethidium bromide (EtBr) and
the recovery of mitochondrial transcription. Northern blots of mitochondrial transcripts ND1, ND5 and nuclear transcript GAPDH 24 h post EtBr
treatment and 1, 2 and 3 day(s) post wash. Mitochondrial transcripts ND1 and ND5 were inhibited by EtBr treatment and recovered post wash; there
was no effect on GAPDH. (F) Effect of 6-methlypurine on POLRMT-catalyzed transcription in vivo. Northern blots of ND1, ND5 and GAPDH after EtBr
treatment and recovery in the presence of 6-methylpurine.
doi:10.1371/journal.ppat.1003030.g001
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Utilization of the antiviral ribonucleoside triphosphates by
POLRMT was determined by using RNA-primed DNA templates
containing the complementary base residue as the first templating
base (Figure 1B). Initial assays determined the fraction of primer
extended after a 30 s incubation of POLRMT in the presence of
each nucleotide substrate at a concentration of 500 mM normal-
ized to correct nucleotide utilization (Figure 1C and D). Under
these conditions, all of the antiviral analogues tested except for 29-
deoxy-29-fluoro-29-C-methyluridine were incorporated much
more efficiently than ribavirin (compare all lanes to lane 8 of
Figure 1C and D). This initial screen clearly indicates that
POLRMT nucleotide substrate specificity is quite relaxed with
respect to non-natural functional groups.
In order to more accurately and quantitatively compare the
efficiency of incorporation for each analogue, we evaluated the
kinetics of incorporation as a function of analogue concentration
and used these data to determine the maximal rate constant for
incorporation (kpol) and apparent dissociation constant (Kd,app)
(Figures S1, S2 and S3). These values are reported in Table 2
for all of the analogues. The incorporation efficiency (kpol/Kd,app) of
each analogue was less than that of the correct nucleotide by at
least an order of magnitude (Table 2). Only one analogue (29-
deoxy-29-fluoro-29-C-methyluridine) was incorporated with an
efficiency less than ribavirin (Table 2, Figure S2 and S3).
Interestingly, the efficiency of incorporation of the second most
inefficient analogue (29-C-methyl-ATP) was still on the order of
10-fold higher than observed for ribavirin triphosphate (Table 2
and Figure S1).
Next, we determined the effect of 6-methylpurine, one of the
more efficiently-utilized nucleoside substrate analogues, on mito-
chondrial transcription in Huh-7 cells (Figure 1E and F). We
chose to evaluate this analogue because it is the only one that will
change the basepairing properties of the base if incorporated and
perhaps alter the structure, stability and/or function of mitochon-
drial RNA. Briefly, mitochondrial transcription was inhibited by
treatment of cells with ethidium bromide (EtBr, 50 ng/mL). Levels
of two mitochondrial transcripts (ND1 and ND5) were monitored.
Treatment of cells with EtBr for 24 h was sufficient to reduce both
transcripts to near background levels (ND1 and ND5 in lane
+EtBr of Figure 1E). This treatment had no effect on
transcription by RNA polymerase II (compare GAPDH to ND1
or ND5 in lane +EtBr of Figure 1E). When 6-methylpurine was
added to media after removal of EtBr, the steady state was
reestablished to a level equivalent to that observed when no 6-
methylpurine was present (Figure 1F). However, after prolonged
treatment (3 days) with 6-methylpurine both ND1 and ND5
mitochondrial transcripts were reduced, presumably due to the
incorporation of 6-methylpurine and the instability of these
transcripts in cells. GAPDH also showed some sensitivity to
treatment with 6-methlypurine. Although this result does not
permit us to determine whether or not 6-methylpurine is
incorporated, it clearly shows a discernible phenotype on the
steady-state level of mitochondrial RNA. This circumstance makes
it impossible to use analysis of RNA in cells to rule in or out the
incorporation of an antiviral ribonucleoside that does not inhibit
elongation.
Non-obligate chain terminators inhibit RNA elongation
by POLRMT
The finding that all of the antiviral ribonucleoside triphosphates
tested were incorporated by POLRMT was quite surprising. As
suggested above, the lack of extreme modifications to the bases
may preclude changes to RNA elongation. Several of the most
exciting analogues of past and current anti-HCV ribonucleosides
Table 1. Intracellular metabolism, cytotoxicity (CC50), anti-HCV replicon activity (EC50) and anti-NS5B activity (IC50)
a.
Ribonucleoside [TP] (mM)
b CC50 (mM) EC50 (mM) IC50 (mM)
Huh-7 MT4 Huh-7 MT4 Huh-7 1b NS5B
(5 day) (5 day) replicon cells
29-C-methyladenosine 620620 120610 65622 661 0.4760.04 8.062.3
7-deazaadenosine 3500610 12006200c 0.04660.027 0.02360.010 0.008760.04 .200
3-deazaadenosine 1.060.05 0.5560.02 190 110610 4.061.0 .200
39-deoxyadenosine ,0.1560.05 ,0.260.05 150610 6667 29613 72614
6-methylpurine-riboside 1000645 240061100c 0.10 0.00360.001 0.07560.010 ndd
ribavirin 3063 2462 4064 4065 36614 .1000
29-C-methylguanosine 3.460.33 0.5660.24 .100 .200 3.360.9 0.3260.15
29-C-methylcytidine 6.562.5 2263 770630 2062 2.360.1 0.4760.16
29-deoxy-29-fluorocytidine 2163 4369c 46617 461 46622 .200
49-methylcytidine 0.5060.03 0.1760.03 .1000 .1000 .90 7.866.7
49-azidocytidine 2.6060.20 1.060.10 .1000 460660 1262 2.960.4
29-deoxy-29-fluoro- 29-C-
methyluridinee
250620 ndd 66620 .100 0.1560.03 3.360.4
aValues rounded to two significant figures. All values are the mean 6 s.d. of at least 3 independent experiments done in duplicate or triplicate except for CC50 Huh-7 for
3-deazaadenosine and 6-methylpurine-riboside, which are the average of replicate wells from one experiment.
bIntracellular metabolism [TP] is the amount of nucleoside triphosphate determined from LC/MS/MS analysis and converted from pmol per million cells to intracellular
concentration (mM) using a cellular volume of 2 pL per cell. All data for 10 mM 24 h incubations except where noted otherwise.
cCompounds that showed toxicity in MT4 cells at 10 mM. Incubations were done at 0.1 mM and the intracellular levels dose normalized assuming proportional increase
in intracellular metabolites with extracellular concentrations.
dnot determined.
eTested in the form of monophosphate prodrug GS-7977.
doi:10.1371/journal.ppat.1003030.t001
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contain modifications to the 29 and/or 49 position of the ribose
ring (e.g. 29-C-methyladenosine, 29-C-methylcytidine, 29-C-
methylguanosine and 49-azidocytidine in Figure 1A) [4,9–11].
These modifications may prevent the RdRp from translocating
after analogue incorporation or prevent the appropriate position-
ing of the incoming nucleotide in the active site, thus leading to
premature termination of the viral RNA [4,9–11]. These non-
obligate chain terminators are therefore quite potent as only one
incorporation event per transcript is required to express the
inhibitory activity. This is illustrated in the finding that these
compounds can inhibit HCV NS5B polymerase activity in vitro
quite effectively (Table 1, IC50)
We used the primer extension assay to determine if modifica-
tions to the 29 or 49 positions of the ribose caused defects to
POLRMT elongation. Using the template with thymine as the first
templating base and adenine as the second templating base, the
combination of ATP and UTP led to extension of the RNA primer
by two nucleotides (lane 2 in Figure 2A). As a control for chain
termination, we used the combination of 39-dATP, an obligate
chain terminator, and UTP. As expected, the RNA primer was
extended by only one nucleotide (lane 6 in Figure 2A).
Surprisingly, the combination of 29-C-methyl-ATP and UTP
produced only the +1 extension product, consistent with this
analogue being a non-obligate chain terminator of POLRMT
(lane 3 in Figure 2A).
We performed the complementary experiment for CTP and
analogues thereof using the template with guanine as the first
templating base and thymine as the second templating base
(Figure 2A). The 29-C-methyl, 49-methyl and 49-azido modifica-
tions caused substantial inhibition of RNA primer elongation
(lanes 11, 13 and 14, respectively, in Figure 2A). The 29-deoxy-
29-fluoro modification did not inhibit elongation (lane 12 in
Figure 2A). Lastly, the analogue 29-C-methyl-GTP was also a
non-obligate chain terminator of POLRMT (lane 18 in
Figure 2A)
The availability of nucleosides with chain termination activity
provides the opportunity to determine unambiguously the
potential for the biochemical experiments to predict effects on
mitochondrial transcription in cells. Mitochondrial transcription
was inhibited for 24 h using EtBr. EtBr was removed and replaced
with media lacking nucleoside or containing 29-C-methyladeno-
sine (Figure 2C) or 49-azidocytidine (Figure 2D). Total RNA
was isolated and processed for analysis by northern blotting using
probes for mitochondrial RNAs (ND1 and ND5) and a cellular
RNA control (GAPDH). We observed a dose-dependent reduction
in the abundance of mitochondrial RNAs using both adenosine
and cytidine analogues (Figure 2C and D). The potency of 29-C-
methyladenosine was greater than that of 49-azidocytidine. At a
concentration of 50 mM, 29-C-methyladenosine completely inhib-
ited accumulation of both ND1 and ND5 transcripts (lanes 4, 10
and 16 in Figure 2C). In contrast, 50 mM 49-azidocytidine was
only sufficient to block ND5 accumulation (compare ND1 and
ND5 in lanes 6, 12 and 18 in Figure 2D). ND1 is the first cistron
and ND5 the last cistron of a near 16,000 nt polycistronic pre-
mRNA produced in mitochondria [36]. The content of adenylate
and cytidylate residues is equivalent for both ND1 and ND5. The
Table 2. Kinetic parameters for POLRMT-catalyzed nucleotide incorporationa.
Ribonucleoside triphosphate kpol Kd,app kpol/Kd,app mitovir scoreb,c mitovir scoreb,d
(s21) (mM) (mM21 s21)
ATP (correct) 3062 2062 1.560.3 30e 30e
29-C-methyl-ATP 0.03060.010 5306100 5.762.261025 1.761022 7.161023
7-deaza-ATP 1562 80620 1.960.561021 15 14
3-deaza-ATP 0.1060.01 340640 2.960.561024 3.161024 1.661024
39-dATP 0.7060.02 8.061.0 8.861.061022 1.361022 1.761022
6-methylpurine-TP 3065 280610 1.160.261021 23 27
ribavirin-TP 0.005060.0010 8006100 6.361.561026 1.861024 1.461024
29-dATP 0.2060.01 7006100 2.960.461024 8.561024 8.561024
GTP (incorrect) 0.02060.002 11006200 1.860.461025 9.161023 9.161023
GTP (correct) 2161 5.560.5 3.860.4 21e 21e
29-C-methyl-GTP 0.07060.010 3706130 1.960.761024 6.461024 1.161024
CTP (correct) 2561 2065 1.360.3 23e 23e
29-C-methyl-CTP 0.06060.010 180620 3.360.761024 2.161023 6.461023
29-deoxy-29-fluoro-CTP 0.05060.010 130630 3.861.261024 7.061023 1.261022
49-methyl-CTP 0.04560.010 580640 7.861.861025 3.961025 1.361025
49-azido-CTP 5.161.0 5806230 8.864.061023 2.361022 8.861023
UTP (correct) 1761 2962 0.6060.05 17e 17e
29-deoxy-29-fluoro- 29-C-methyl-UTP 3.460.661024 5506260 6.263.061027 1.061024 ndf
aValues rounded to two significant figures. Standard errors are from non-linear regression fits of data to a hyperbolic model (Figures S1, S2 and S3).
bmitovir score: rate constant for incorporation calculated by using the experimentally determined kinetic parameters, kpol and Kd,app and the intracellular concentration
of nucleoside analog triphosphate [TP] (Table 1); mitovir score = keff (s
21) = (kpol * [TP])/(Kd,app+[TP]).
cmitovir score determined for Huh-7 cells.
dmitovir score determined for MT4 cells.
erate constant for incorporation calculated by using the experimentally determined kinetic parameters, kpol and Kd,app and the intracellular concentration of nucleotide
[TP] (Table S1); keff (s
21) = (kpol * [TP])/(Kd,app+[TP]).
fnot determined.
doi:10.1371/journal.ppat.1003030.t002
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polar effect of 49-azidocytidine inhibition likely reflects the fact
that the probability of incorporation increases as a function
transcript length. Thus, genes near the 59 end will be less
susceptible to termination than genes near the 39 end. That 29-C-
methyladenosine promotes termination becomes even more
convincing by evaluating overexposed blots, which show a ladder
of products that hybridize to the probe only in drug-treated lanes
(Figure S4). Collectively, these data demonstrate that biochem-
ical analysis, which includes in vitro POLRMT-catalyzed nucle-
otide incorporation assays that assess the efficiency of utilization
and inhibition, can predict biological outcomes, thus permitting us
to conclude that inhibition of POLRMT by antiviral ribonucle-
osides must be considered during development of this class of
antiviral agents.
TFIIS prevents inhibition of Pol II transcription by non-
obligate chain terminators
The inability to observe perturbations in the levels of cellular
RNAs derived from nuclear transcription in response to antiviral
ribonucleoside treatment has been interpreted to mean that
nuclear RNA polymerases are unable to use these agents [13,26].
The observation that neither 29-C-methyladenosine nor 49-
azidocytidine had a marked effect on the nuclear transcript
GAPDH (Figure 2C and D) is consistent with these previous
studies. In order to test this possibility directly, we used
transcription elongation complexes with Pol II isolated from
calf thymus and scaffolds capable of templating adenosine
analogues (C12 in Figure 3A) or cytidine analogues (A11 in
Figure 3A) as the first nucleotide [37,38]. With the exception of
ribavirin triphosphate (RTP), all of the purine nucleotide
analogues were efficiently incorporated by Pol II when the
proofreading activity of TFIIS was absent (lanes 1–8 in
Figure 3B). The presence of TFIIS inhibited accumulation of
the analogues in RNA (lanes 9–15 in Figure 3B). In order to
determine the consequence of analogue incorporation on
elongation, the elongation reaction was performed in the
presence of purine analogue and the next two nucleotides,
UTP and CTP (Figure 3C). With the exception of 29-C-methyl-
ATP, all analogues with a 39-OH supported extension of the
RNA to the n+4 position in the absence of TFIIS (lanes 2–6 in
Figure 3C). Worth noting, RMP incorporation failed to support
robust extension (lane 8 in Figure 3C). We conclude that non-
obligate chain terminators of HCV RdRp have the same impact
on Pol II. Again, the presence of TFIIS antagonized production
of fully elongated RNA (panel +TFIIS in Figure 3C). Interest-
ingly, the observation that TFIIS only partially reverses the
effects of 6-methlypurine utilization (Figure 3B and C) is
consistent with the sensitivity of GAPDH transcripts in cells
when treated with this nucleoside (Figure 1F).
We performed an analogous set of experiments with the cytidine
analogues known to exhibit non-obligate chain termination
activity with HCV RdRp (Figure 3D). Unexpectedly, the 29-
fluoro, 49-methyl and 49-azido modifications permitted elongation
Figure 2. Non-obligate chain terminators inhibit RNA elongation by POLRMT. (A) Non-obligate chain termination of RNA synthesis in vitro.
Products from POLRMT-catalyzed nucleotide incorporation in the presence of the next correct nucleotide substrate, UTP or ATP. Reactions proceeded
for 10 min. Reactions containing ATP, 7-deaza-ATP, 3-deaza-ATP, 6-methylpurine-TP, ribavirin-TP, CTP,29-deoxy-29-fluoro-CTP and GTP were readily
extended to n+2 product by POLRMT. Reactions containing 29-C-methyl-ATP, 29-C-methyl-CTP, 49-methyl-CTP, 49-azido-CTP and 29-C-methyl-GTP
were unable to be extended to n+2, demonstrating the ability of these nucleoside analogs to be non-obligate chain terminators for POLRMT once
incorporated in nascent RNA. 39-dATP and 39-dCTP were used as positive controls. (B–D) Production of full-length mitochondrial RNA transcripts in
cells is impaired in the presence of 29-C-methyladenosine and 49-azidocytidine. (B) Experimental design. Huh-7 cells were treated with EtBr for 24 h to
deplete mitochondrial transcripts from cells, washed, treated with 29-C-methyladenosine or 49-azidocytidine for 1, 2 and 3 days, total RNA isolated
and Northern blots performed. Northern blots of ND1, ND5 and GAPDH after EtBr treatment and recovery in the presence of (C) 29-C-
methyladenosine and (D) 49-azidocytidine. Cells treated with a minimum of 50 mM 29-C-methyladenosine showed specific inhibition of mitochondrial
transcription and the inability to produce both ND1 and ND5 transcripts, whereas a minimum of 50 mM 49-azidocytidine only inhibited production of
ND5; GAPDH was unaffected by treatment with 50 mM 29-C-methyladenosine or 49-azidocytidine. At higher concentrations of 49-azidocytidine
GAPDH showed some sensitivity.
doi:10.1371/journal.ppat.1003030.g002
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by Pol II in the absence of TFIIS. TFIIS efficiently prevented their
incorporation and/or extension (Figure 3D). Curiously, even
though the 29-C-methyl modification prevented further elonga-
tion, TFIIS did not remove the analogue on the timescale of the
experiment (lanes 1 and 7 of Figure 3D).
We quantified the ability of TFIIS to prevent accumulation of
the ribonucleoside analogues in RNA (Figure 3E). Two classes of
analogues were identified: those that were excised by TFIIS 80%
or better and those that were not. Reduced excision of the
analogues containing a 29-C-methyl substituent was a kinetic
phenomenon as longer incubations led to greater excision (Figure
S5). The efficiency with which TFIIS functions to excise
ribonucleoside analogues extends to that from Saccharomyces
cerevisiae (Figure S6).
Predicting adverse effects of antiviral ribonucleosides
during preclinical development: Use of MT4 cells and the
mitovir score
Why are the adverse effects of antiviral ribonucleoside
analogues not recognized sooner? Validated cell model system(s)
capable of revealing the adverse effects are lacking. For this study,
we have employed three cell lines, with Huh-7 and MT4 cells
being the workhorses. The nucleoside analogue triphosphate pools
were equivalent in these cell lines (Table 1). Metabolism of the
antiviral ribonucleosides tested here to the triphosphate were
within 2- to 3-fold of each other (Table 1). In addition, levels of
cytotoxicity caused by the analogues as reported by CC50 values
exhibited correlation between the MT4 and Huh-7 cell lines
Figure 3. TFIIS prevents accumulation of antiviral nucleotides in Pol II transcripts. (A) Schematic of synthetic nucleic scaffolds for
transcription elongation complex (TEC) assembly with calf thymus Pol II. The first templating base is underlined. The TEC with 11-nt RNA (TEC-A11)
was assembled using TDS50, NDS50 and RNA9 (see Table S2 for the complete oligonucleotide sequences) in the presence of 10 mM each GTP and
ATP (TEC-A11) and purified from the unincorporated DNA, RNA and NTPs; TEC-C12 was obtained by addition of 10 mM CTP to TEC-A11. (B) Reaction
products from Pol II-catalyzed nucleotide incorporation in the absence and presence of TFIIS. The concentration of unmodified substrate NTP and
analogs were 500 mM; TFIIS was added at 10 mM. Reactions proceeded for 2 min. Reactions with ribavirin-TP proceeded for 10 min. (C,D) Reaction
products from Pol II-catalyzed nucleotide incorporation in the presence of the next correct nucleotide substrate. The concentration of the unmodified
substrate NTP and analogs were 500 mM; TFIIS was added at 10 mM. Reactions proceeded for 2 min. Reactions with ribavirin-TP, 49-methyl-CTP and
49-azido-CTP proceeded for 10 min. (E) Percent inhibition by TFIIS on Pol II nucleoside analog incorporation.
doi:10.1371/journal.ppat.1003030.g003
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r = 0.8161, Figure 4A). In general, MT4 cells were an order of
magnitude more sensitive to the antiviral nucleosides than Huh-7
cells (Table 1). The cytotoxicity observed in MT4 cells was only
weakly correlated with the intrinsic efficiency (kpol/Kd,app) with
which POLRMT incorporated the analogue r = 20.4196,
Figure 4B). However, when the rate constant for incorporation
was calculated using the intracellular concentration of the
triphosphorylated form of the analogue (Table 2, mitovir score),
this parameter was strongly correlated with the observed
cytotoxicity in MT4 cells (r = 20.7182, Figure 4C). We refer
to this constant, the rate constant for analogue incorporation by
POLRMT adjusted for intracellular concentration of the tripho-
sphorylated form of the analogue, as the mitovir score as it
provides a prediction of POLRMT-mediated mitochondrial
dysfunction caused by the antiviral ribonucleoside. Normalizing
the mitovir score to account for the presence of the nucleotide
with which the analogue competes did not further strengthen the
correlation (P = 0.0064, Figure 4D). The correlation between
cytotoxicity and the mitovir score was weaker in Huh-7 cells
(r = 20.3958, Figure 4E) a less robust cell line for cytotoxicity
studies than the MT4 line, yet a correlation is discernible and
incorporation of the analogues into mitochondrial RNA clearly
occurs (Figures 2C and 2D). We suggest that the use of the
MT4 cell line in combination with the mitovir score, which
represents the combination of biochemical analysis and intracel-
lular metabolism, will be sufficient to identify antiviral ribonu-
cleosides during preclinical development with the potential to
cause adverse effects.
Discussion
Maintenance, replication and expression of the mitochondrial
genome (mtDNA) is absolutely essential for cell function because
mtDNA encodes 13 proteins required for oxidative phosphoryla-
tion, as well as the tRNAs and rRNAs essential to their production
[36]. However, cells have far more mtDNA than required to
support oxidative phosphorylation; therefore, a substantial reduc-
tion in mtDNA copy number is required for manifestation of a
clinically apparent phenotype [22,24]. Therefore, adverse effects
of drugs that interfere with replication and/or expression of
mtDNA may not be readily apparent in mammalian cells or
animal models on the timescale of preclinical testing [28]. In
addition, because mammalian cell lines are often grown in high
concentrations of glucose, oxidative phosphorylation is not
necessarily required for ATP production in cells, the so called
Crabtree effect [39]. Under these conditions, even severe
mitochondrial dysfunction would have little to no impact on
intracellular ATP levels.
A high proportion of anti-HCV ribonucleosides have entered
the clinic just to have development discontinued due to adverse
effects in patients [4,10]. The molecular bases for these effects are
either not known or not reported. We have shown here for the first
time that antiviral ribonucleoside triphosphates are substrates for
POLRMT both in vitro and in cells (Figures 1 and 2 and
Table 2), suggesting that patient toxicity in the clinic may be
related to mitochondrial dysfunction. That a mitochondrial
polymerase is an off target for an antiviral agent is not surprising
Figure 4. Predicting adverse effects of antiviral ribonucleosides during preclinical development: The mitovir score. Correlations
between (A) cytotoxicity in Huh-7 cells and MT4 cells (Table 1, CC50), (B) cytotoxicity in MT4 cells (Table 1, CC50) and the efficiency of nucleotide
incorporation (Table 2, kpol/Kd,app), (C) cytotoxicity in MT4 cells (Table 1, CC50) and mitovir score for MT4 cells (Table 2), (D) cytotoxicity in MT4
cells (Table 1, CC50) and the mitovir score for each analogue corrected to account for the presence of the nucleotide with which the analogue
competes, ATP or CTP, and (E) cytotoxicity in Huh-7 cells (Table 1, CC50) and mitovir score for Huh-7 cells (Table 2). Error bars represent s.d.
Nonparametric (Spearman) correlations with r values shown. In parentheses are one-tailed P-values calculated from Spearman coefficients to provide
a measure of statistical significance of correlation.
doi:10.1371/journal.ppat.1003030.g004
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as this problem has been well documented for Pol c, resulting from
nucleoside NRTIs used in the treatment of HIV infection
[17,21,23]. What is surprising, however, is the absence of any
reported attempts to evaluate POLRMT.
POLRMT is a single-subunit RNA polymerase that is a
member of the bacteriophage T7 family of RNA polymerases.
Only recently has any mechanistic [30] or structural [40]
information become available for this enzyme. The active sites
of POLRMT and T7 RNA polymerase (T7 RNAP) differ by only
one amino acid [40]. Interestingly, POLRMT can incorporate
ribavirin (Table 2), but T7 RNAP fails to utilize this antiviral
ribonucleotide during in vitro transcription reactions [41].
Checkpoints for incorporation fidelity by POLRMT discovered
to date reside at the active site and represent conformational
changes observed for all classes of nucleic acid polymerases [30].
The observed differences in fidelity between POLRMT and T7
RNAP may suggest that remote sites may be controlling fidelity
[30], thus complicating the use of homology models for the
identification of nucleotide modifications that will prevent
utilization by POLRMT.
Our biochemical assays are able to predict outcomes in cells
when non-obligate chain terminators are used (Figure 2). This
observation suggests that mitochondrial factors do not exist to
cleave the nascent RNA associated with a stalled elongation
complex that would be analogous to Gre and TFIIS factors of
multi-subunit RNA polymerases [42]. We conclude that the only
determinant of the incorporation fidelity observed in cells other
than the intrinsic efficiency with which POLRMT utilizes the
antiviral ribonucleotide is the size of the intracellular antiviral
ribonucleoside triphosphate (rNTP) pool. Essentially no informa-
tion exists on differences between antiviral ribonucleoside metab-
olism in the cytoplasm relative to the mitochondrial matrix.
However, entry of antiviral rNTPs into mitochondria through
nucleotide transporters would eliminate an absolute requirement
for intramitochondrial metabolism of antiviral ribonucleosides
[23,43]. To a first approximation, it is reasonable to assume that
the total pool of antiviral rNTPs likely reflects the magnitude of the
intramitochondrial pool as shown here for 29-C-methyladenosine
(Table S1).
The ability of TFIIS to excise most ribonucleotide analogues
studied here demonstrates a robust, active mechanism in
mammals to protect the integrity of RNA produced in the nucleus
from insults by non-natural nucleotides (Figure 3). This property
of TFIIS is even retained in yeast (Figure S6). Prokaryotes have
similar proofreading factors that may serve a similar role. It is
tempting to speculate that the evolution of these factors may have
facilitated survival in environments where ribonucleoside ana-
logues were used to secure a niche and fend off predator
organisms.
The absence of an active mechanism for the removal of
nucleotides with non-natural bases and ribose configurations and/
or modifications incorporated by POLRMT suggests that it may
be difficult to avoid off-target effects of antiviral ribonucleosides.
The availability of biochemical tools to elucidate the nucleotide
specificity of POLRMT empirically will contribute substantially to
the identification of modifications capable of enhancing the
specificity of antiviral ribonucleosides.
Manifestation of the side effects of NRTIs can take decades,
perhaps a reflection of the substantial copy number of mtDNA, the
quiescent nature of much mtDNA and/or the requirement for cell
cycling to observe mtDNA replication [17,22–24]. In contrast,
expression of mtRNA is essential in all cells. Therefore, the
manifestation of clinical signs in response to interference with
mitochondrial transcription might be expected to occur more
rapidly than observed for NRTIs. Interestingly, not all patients
treated with the antiviral ribonucleosides under investigation here
presented with adverse effects, suggesting that other conditions
may contribute to a patient’s response to antiviral ribonucleosides.
One might imagine that individuals with undiagnosed mitochon-
drial disease would exhibit enhanced sensitivity to antiviral
ribonucleotides capable of being incorporated into mitochondrial
RNA. It is well documented that children with mitochondrial
disease exhibit adverse effects to antibiotics like chloramphenicol
for which the mitochondrial ribosome is an off target [44].
Evaluation of the exome and mtDNA sequences of patients
exhibiting adverse effects to antiviral ribonucleosides may uncover
susceptibility genes. If this hypothesis is correct, then antiviral
ribonucleoside programs that have been discontinued may still
have value for large segments of the population.
We propose the mitovir (mitochondrial dysfunction caused by
antiviral ribonucleosides) score as a parameter that can be
determined easily during preclinical studies to identify antiviral
ribonucleosides whose impact on mitochondrial function should
be rigorously investigated (Table 2). This score is essentially an
effective rate constant for utilization of the antiviral rNTP
calculated by using the values for kpol and Kd,app determined in
vitro (Table 2) and the value for the concentration of antiviral
rNTP present in cells (Table 1). The quotient of the mitovir score
for the antiviral rNTP divided by that for the rNTP with which the
antiviral rNTP competes yields an approximate frequency of
incorporation of the antiviral ribonucleotide. Both of these
parameters correlate well with values for CC50 measured in
MT4 cells (Figure 4C and 4D). A correlation was more difficult
to observe in Huh-7 cells (Figure 4E). The lack of robust
reporting in Huh-7 cells may be a reflection that ATP levels are
maintained by aerobic glycolysis [39]. It is possible that MT4 cells
require mitochondrial function for growth in culture, even in the
presence of high concentrations of glucose [39]. Because there is
no net ATP produced in mammalian cells when galactose is used
as the carbon source, oxidative phosphorylation becomes essential
for cellular energetics [39]. Perhaps Huh-7 cells and other cell lines
adapted for growth in galactose will be able to link antiviral
ribonucleoside induced dysfunction of mitochondria to production
of ATP and cell viability. Under these conditions, a stronger
correlation with the mitovir score may be revealed. These findings
also underscore the need to utilize cell lines in preclinical analogue
screening studies that authentically reveal mitochondrial status.
The mitovir score for GTP or 29-dATP, models for ‘‘mis-
incorporation’’ events which POLRMT likely evolved to evade,
indicate a frequency of misincorporation of 1 in 3,300 or 1 in
35,000, respectively (Table 2). Given that the primary coding
transcript produced is on the order 16,000 nucleotides in length,
the data suggest that transition mutations are better tolerated than
altered ribose configuration. Lethal mutagens like ribavirin may
therefore represent a class of antiviral agents with a higher cellular
tolerability. The mitovir score for ribavirin predicts a frequency of
incorporation of 1 in 160,000, perhaps establishing an upper limit
for an antiviral ribonucleoside that is miscoding but fails to inhibit
transcription elongation.
The case of 49-azidocytidine supports the utility of the mitovir
score. Preclinical studies, including long-term studies in mice and
dogs, failed to reveal any toxicity [4,10]. Indeed, even in MT4
cells, the value for the CC50 was high corresponding to the low
intracellular level of triphosphorylated metabolite (Table 1). The
mitovir score predicts an incorporation frequency of 1 in 700
nucleotides (Table 2). This value suggests a clear, negative impact
on mitochondrial transcription in cells (Figure 2D). While the
mitovir scores are not as high as those for 49-azidocytidine, we’ve
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found that 29-C-methyl analogues are substrates for POLRMT
and that 29-C-methyladenosine-triphosphate is formed within
mitochondria and selectively inhibits production of mitochondrial
transcripts in cells. The relevance of these findings to clinical
observation with related compounds requires further study. In
contrast, the currently used nucleoside analog ribavirin was found
to be an exceedingly poor substrate for POLRMT. We have also
found 29-deoxy-29-fluoro-29-C-methyluridine-triphosphate,
formed by mericitabine [45] and GS-7977 [34], to be an even
worse substrate for POLRMT than ribavirin triphosphate. The
combined biochemical and biological approaches reported here
should facilitate the development of highly efficacious therapeutic
ribonucleotide analogues with lower potential for toxicity.
Materials and Methods
Human mitochondrial RNA polymerase nucleotide
incorporation assays
Nucleotide incorporation experiments were performed as
described previously [30]. Briefly, elongation complexes were
formed by incubating POLRMT with the appropriate primed
template, mixed with appropriate nucleoside triphosphate sub-
strate and quenched by addition of EDTA. Products were
analyzed be denaturing PAGE and quantitated by phosphorima-
ging. All details and equations employed are provided in Protocol
S1. POLRMT was expressed and purified as described previously
[30]. POLRMT of comparable activity and purity can be obtained
from INDIGO Biosciences, Inc. (State College, PA).
Pol II elongation complex assembly and transcription
elongation assays
The elongation complexes of yeast or bovine Pol II were
assembled with RNA and DNA oligonucleotides as indicated in
the Figure Legends. The assembly and purification of the
elongation complexes was performed by membrane filtration as
previously described in detail [37]. Transcription elongation assays
and the detection of transcription products were performed as
described previously [37,38]. Human recombinant TFIIS was
expressed and purified as described in [46]. Yeast TFIIS was
expressed and purified according to [47] using expression
construct generously provided by C. Kane.
HCV NS5B enzymatic assays
HCV NS5B-dependent RNA elongation activity was assayed
using a heteropolymeric RNA template as described previously
[48]. Detailed protocols are provided in Protocol S1.
Cell lines
Huh-7 cells were maintained in growth medium containing
Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAX
(Gibco, Carlsbad, CA), supplemented with 10% fetal bovine
serum (FBS) (HyClone, Logan, UT), 100 units/mL penicillin,
100 mg/mL streptomycin (Gibco, Carlsbad, CA) and 0.1 mM
non-essential amino acids (Gibco, Carlsbad, CA). For Huh-7 cells
grown in galactose media, growth medium contained DMEM (-
glucose) (Gibco, Carlsbad, CA), supplemented with 5 mM HEPES
(Sigma), 10 mM galactose (Sigma), 1 mM sodium pyruvate
(Cellgro), 10% FBS, 100 units/mL penicillin and 100 mg/mL
streptomycin. Cells were adapted for 3 weeks in galactose media
before treating with compounds. MT-4 cells were obtained from
the NIH AIDS Research and Reference Reagent Program
(Germantown, MD), and maintained in RPMI-1640 medium
(IrvineScientific, Santa Ana, CA) supplemented with 100 units/
mL penicillin, 100 mg/mL streptomycin, 2 nM L-glutamine and
10% FBS. MT-4 cells were passed twice a week and maintained at
densities below 0.66106 cells/mL. HeLa S3 cells were obtained
from ATCC (Manassas, VA), and maintained in DMEM
supplemented with 10% FBS, 100 units/mL penicillin and
100 mg/mL streptomycin.
Intracellular metabolism
Cells were treated for 24 h with 10 mM of each ribonucleoside
analog. For analogs that caused toxicity at 10 mM, triphosphate
levels had to be dose normalized after being determined with
incubations at 0.1 mM. After 24 hours, cells were counted and
isolated by spinning through oil essentially as previously described
[49], except that the oil layer was washed with ice cold normal
saline instead of phosphate buffered saline. After storing samples in
70% methanol at 220uC for at least overnight to facilitate cell
lysis, cell (Huh-7 and MT4) or mitochondrial (from HeLa S3 cells)
lysates were dried and suspended in 3 mM ammonium formate
(pH 5) with 10 mM dimethylhexylamine in water at a concentra-
tion of extract from 100,000 cells/10 mL for Huh-7 and MT4 cells
or extract from mitochondria isolated from 1 million cells/10 mL
for mitochondria isolated from HeLa S3 cells and 10 mL of the
samples were analyzed by LC/MS/MS. Ribonucleoside triphos-
phates were quantified by ion pairing LC coupled to positive mode
MS/MS essentially as described previously [50]. Detailed proto-
cols are provided in Protocol S2.
Cytotoxicity assays
The 5-day cytotoxicity of compounds was performed using
CellTiter Glo viability reagents (Promega). Detailed protocols are
provided in Protocol S2.
HCV replicon assays
A Huh-7 cell line carrying a Renilla luciferase HCV genotype
1b replicon was used to assess antiviral activity of compounds as
described previously [51,52]. Detailed protocols are provided in
Protocol S2.
Mitochondrial transcription in cells
Cells were treated with 50 ng/mL ethidium bromide and
placed at 37uC in a 5% CO2 incubator to deplete mitochondrial
transcripts from cells. After 24 h, media was removed, cells were
washed with PBS and fresh media was added containing the
appropriate compound at various concentrations. DMSO at 0.5%
was used as a negative control. Cells were placed at 37uC in a 5%
CO2 incubator for one, two or three days. Every 24 h the media
was removed and replaced with fresh media containing the
appropriate compound. At the indicated time point, media was
removed, cells washed with PBS, harvested and Northern blots
performed.
Northern blot analysis
Northern blots were performed for the detection of mito-
chondrial transcripts ND1 and ND5 and nuclear transcript
GAPDH. Cells were lysed by adding TRI Reagent (Sigma, Cat#
T94247), RNA isolated and separated on a 1% denaturing
agarose gel. RNA was transferred to nylon membrane, slightly
dried and RNA was crosslinked to the membrane using a UV
Crosslinker (Stratalinker 2400, Stratagene). Hybridization was
performed in a modified Church’s buffer for 16 h at 65uC.
Membranes were visualized by using a PhosphorImager (GE).
Hybridization probes were made by PCR. Detailed protocols are
provided in Protocol S2.
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Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0
(La Jolla, CA). Nonparametric Spearman correlation coefficients
(r) were computed and from these values one-tailed tests for
statistical significance (P-values) were calculated. The s.d. and
s.e.m values are indicated where appropriate.
Supporting Information
Figure S1 Kinetic parameters for POLRMT-catalyzed
nucleotide incorporation: Adenosine analogs. Kinetics of
nucleotide incorporation as a function of nucleoside triphosphate
concentration for (A) ATP, (B) 29-C-methyl-ATP, (C) 7-deaza-
ATP, (D) 3-deaza-ATP, (E) 39-dATP, (F) 6-methylpurine-TP and
(G) ribavirin-TP. Observed rate constants (kobs) for nucleotidyl
transfer at various concentrations of nucleotide substrate were
obtained by fitting either product-versus-time data or relative
fluorescence-versus-time data to an equation defining a single
exponential. Values for kobs were then plotted as a function of
nucleoside triphosphate concentration and fit to a hyperbola,
yielding the maximal rate constant for incorporation (kpol) and
apparent dissociation constant (Kd,app).
(PDF)
Figure S2 Kinetic parameters for POLRMT-catalyzed
nucleotide incorporation: Cytidine analogs. Kinetics of
nucleotide incorporation as a function of nucleoside triphosphate
concentration for (A) CTP, (B) 29-C-methyl-CTP, (C) 29-deoxy-29-
fluoro-CTP, (D) 49-methyl-CTP and (E) 49-azido-CTP. Observed
rate constants (kobs) for nucleotidyl transfer at various concentra-
tions of nucleotide substrate were obtained by fitting either
product-versus-time data or relative fluorescence-versus-time data
to an equation defining a single exponential. Values for kobs were
then plotted as a function of nucleoside triphosphate concentration
and fit to a hyperbola, yielding the maximal rate constant for
incorporation (kpol) and apparent dissociation constant (Kd,app).
(PDF)
Figure S3 Kinetic parameters for POLRMT-catalyzed
nucleotide incorporation: Guanine and uridine analogs.
Kinetics of nucleotide incorporation as a function of nucleoside
triphosphate concentration for (A) GTP, (B) 29-C-methyl-GTP,
(C) UTP and (D) 29-deoxy-29-fluoro-29-C-methyl-UTP. Observed
rate constants (kobs) for nucleotidyl transfer at various concentra-
tions of nucleotide substrate were obtained by fitting either
product-versus-time data or relative fluorescence-versus-time data
to an equation defining a single exponential. Values for kobs were
then plotted as a function of nucleoside triphosphate concentration
and fit to a hyperbola, yielding the maximal rate constant for
incorporation (kpol) and apparent dissociation constant (Kd,app).
(PDF)
Figure S4 Production of full-length mitochondrial RNA
transcripts is impaired in the presence of 29-C-methy-
ladenosine: Overexposed Northern blots showing a
ladder of truncated products. Northern blot of ND5 after
EtBr treatment and recovery in the presence of 29-C-methylade-
nosine. The blot was overexposed and shows a ladder of truncated
RNA products that accumulate over time from cells treated with
29-C-methyladenosine.
(PDF)
Figure S5 Kinetics of TFIIS-mediated RNA cleavage.
(A,B) Kinetics of TFIIS-mediated RNA cleavage subsequent to
AMP, 29C-methyl-AMP and 39-dAMP incorporation by calf
thymus Pol II. TEC-C12 was incubated with 500 mM ATP, 29-C-
methyl-ATP or 39-dATP for 2 min at which point TFIIS added to
1 mM final concentration for the indicated time. The percentage of
A13 remaining was plotted as a function of time and fit to a single
exponential yielding observed rate constants of TFIIS-mediated
RNA cleavage of 0.04060.006, 0.006060.0020, 0.1460.02 s21
after incorporation of AMP, 29-C-methyl-AMP or 39-dAMP
respectively. (C,D) Kinetics of TFIIS-mediated RNA cleavage
subsequent to CMP, 29C-methyl-CMP and 49-azido-CMP
incorporation. TEC-A11 was incubated with 500 mM CTP or
29-C-methyl-CTP for 2 min or 49-azido-CTP for 10 min at which
point TFIIS added to 1 or 10 mM final concentration for the
indicated time. The percentage of C12 remaining was plotted as a
function of time and fit to a single exponential yielding observed
rate constants of TFIIS-mediated RNA cleavage of 0.08860.003,
0.001860.0003, 0.1360.01 and 0.1360.01 s21 after incorpora-
tion of CMP, 29-C-methyl-CMP or49-azido-CMP respectively. At
10 mM TFIIS the observed rate constant of TFIIS-mediated RNA
cleavage after incorporation of 29-C-methyl-CMP was
0.004560.0004 s21.
(PDF)
Figure S6 Nucleoside analog incorporation and exten-
sion of the resulting products catalyzed by yeast Pol II.
(A) Schematic of synthetic nucleic scaffolds for transcription
elongation complex (TECs) assembly with yeast Pol II. The TECs
were assembled using TDS76 and NDS79 and either RNA9 in the
presence of 10 mM GTP (TEC-G10) or RNA 7(20) in the presence
of 10 mM each ATP, GTP and UTP (TEC-A11); the TECs were
purified from the unincorporated DNA, RNA and NTPs before
addition of the appropriate nucleoside analog triphosphate. The
oligonucleotide sequences are in Table S2. (B,C) Reaction
products from Pol II-catalyzed nucleotide incorporation in the
absence and presence of TFIIS. The concentration of the
unmodified substrate NTP and analogs were 500 mM; TFIIS
was added at 10 mM. Reactions proceeded for 1 min. Reaction
with ribavirin-TP proceeded for 10 min. (D,E) Reaction products
from Pol II-catalyzed nucleotide incorporation in the presence of
the next correct nucleotide substrate. The concentration of the
unmodified substrate NTP and analogs were 500 mM; TFIIS was
added at 10 mM. Reactions proceeded for 1 min. Reaction with
ribavirin-TP proceeded for 10 min. (F) Percent inhibition by
TFIIS on Pol II nucleoside analog incorporation.
(PDF)
Protocol S1 Polymerase-catalyzed nucleotide incorpo-
ration assays.
(DOCX)
Protocol S2 Evaluation of nucleoside analogs in cells.
(DOCX)
Table S1 Mitochondrial ribonucleoside triphosphate
concentrations.
(DOCX)
Table S2 Oligonucleotides used for the elongation
complex assembly.
(DOCX)
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